Discontinued ProductUnfortunately L803 (Cat. No. 2235) has been withdrawn from sale for commercial reasons.
Novel phosphopeptide derived from GSK-3 recognition motif that acts as a substrate-competitive inhibitor of GSK-3β (IC50 = 150 μM). Displays minimal inhibition of Cdc2, MAPK, PKA, CK2, PKCδ and PKB at 200 μM.
Sold under licence from Tel Aviv University Future Technology LP
(Modifications: Ser-10 = pSer)
|Storage||Desiccate at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Preparing Stock Solutions
The following data is based on the product molecular weight 1198.23. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||0.83 mL||4.17 mL||8.35 mL|
|5 mM||0.17 mL||0.83 mL||1.67 mL|
|10 mM||0.08 mL||0.42 mL||0.83 mL|
|50 mM||0.02 mL||0.08 mL||0.17 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Plotkin et al (2003) Insulin mimetic action of synthetic phosphorylated peptide inhibitors of glycogen synthase kinase-3. J.Pharmacol.Exp.Ther. 305 974 PMID: 12626660
View Related Products by Target
View Related Products by Product Action
Keywords: L803, supplier, Substrate-competitive, inhibitors, inhibits, GSK-3, Glycogen, Synthase, Kinases, 3, Carbohydrate, Metabolism, Glycogen, Synthase, Kinase, 3, Tocris Bioscience
Citations for L803
Citations are publications that use Tocris products.
Currently there are no citations for L803.
Literature in this Area
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.